These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20615173)

  • 21. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
    Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
    Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
    Hoyle M; Rogers G; Moxham T; Liu Z; Stein K
    Value Health; 2011 Dec; 14(8):1057-67. PubMed ID: 22152175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.
    Gordois A; Scuffham P; Warren E; Ward S
    Br J Cancer; 2003 Aug; 89(4):634-40. PubMed ID: 12915870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
    Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
    Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
    Vinogradova OIu; Turkina AG; Vorontsova AV; Chelysheva EIu; Gusarova GA; Kuznetsov SV; Goriacheva SR; Sokolova MA; Abakumov EM; Stakhina OV; Domracheva EV; Misiurin AV; Khoroshko ND
    Ter Arkh; 2009; 81(7):41-6. PubMed ID: 19708572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
    Skrepnek GH; Ballard EE
    Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
    Saglio G; Hochhaus A; Goh YT; Masszi T; Pasquini R; Maloisel F; Erben P; Cortes J; Paquette R; Bradley-Garelik MB; Zhu C; Dombret H
    Cancer; 2010 Aug; 116(16):3852-61. PubMed ID: 20564086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
    Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Bcr-Abl-positive leukemias with dasatinib.
    Hochhaus A
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dasatinib: BMS 354825.
    Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
    Sillaber C; Herrmann H; Bennett K; Rix U; Baumgartner C; Böhm A; Herndlhofer S; Tschachler E; Superti-Furga G; Jäger U; Valent P
    Eur J Clin Invest; 2009 Dec; 39(12):1098-109. PubMed ID: 19744184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
    Ault P
    Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.
    Sheng G; Chen S; Dong C; Zhang R; Miao M; Wu D; Tan SC; Liu C; Xiong T
    J Med Econ; 2017 Apr; 20(4):371-381. PubMed ID: 27936995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of low-dose dasatinib in an elderly patient with chronic myelogenous leukemia (CML)].
    Takagi Y; Aota Y; Gotoh A; Sakurai M
    Gan To Kagaku Ryoho; 2010 Nov; 37(11):2213-5. PubMed ID: 21084830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Keam SJ
    BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCR-ABL mutant kinetics in CML patients treated with dasatinib.
    Nicolini FE; Chabane K; Tigaud I; Michallet M; Magaud JP; Hayette S
    Leuk Res; 2007 Jun; 31(6):865-8. PubMed ID: 17208297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
    Fu J; Liu Y; Lin H; Wu B
    Clin Drug Investig; 2018 Dec; 38(12):1167-1178. PubMed ID: 30232698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.